Items where authors include "de Bono, J."

Article

Rekowski, J. orcid.org/0000-0002-5207-3864, Guo, C., Solovyeva, O. et al. (35 more authors) (2025) CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trials. eClinicalMedicine, 79. 102987. ISSN 2589-5370

Ursino, M., Villacampa, G., Rekowski, J. orcid.org/0000-0002-5207-3864 et al. (34 more authors) (2025) SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols. eClinicalMedicine, 79. 102988. ISSN 2589-5370

Rescigno, P., Porta, N., Finneran, L. et al. (26 more authors) (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205. 114103. ISSN 0959-8049

Al-janabi, H., Moyes, K., Allen, R. et al. (14 more authors) (2024) Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy. Journal for ImmunoTherapy of Cancer, 12 (7). e009368. ISSN 2051-1426

Yap, C. orcid.org/0000-0002-6715-2514, Rekowski, J. orcid.org/0000-0002-5207-3864, Ursino, M. orcid.org/0000-0002-5709-4322 et al. (32 more authors) (2023) Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT dose-finding extension (SPIRIT-DEFINE) guidance. BMJ, 383. e076386. ISSN 1759-2151

Yap, C. orcid.org/0000-0002-6715-2514, Solovyeva, O. orcid.org/0000-0001-7828-4099, de Bono, J. orcid.org/0000-0002-2034-595X et al. (32 more authors) (2023) Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT dose-finding extension (CONSORT-DEFINE) guidance. BMJ, 383. e076387. ISSN 0959-8138

Macaulay, V.M. orcid.org/0000-0001-8659-0192, Lord, S. orcid.org/0000-0001-7946-5609, Hussain, S. orcid.org/0000-0003-1552-511X et al. (11 more authors) (2023) A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer. British Journal of Cancer, 129 (6). pp. 965-973. ISSN 0007-0920

Solovyeva, O. orcid.org/0000-0001-7828-4099, Dimairo, M. orcid.org/0000-0002-9311-6920, Weir, C.J. orcid.org/0000-0002-6494-4903 et al. (20 more authors) (2023) Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study. BMC Medicine, 21 (1). 246. ISSN 1741-7015

Scott, E., Hodgson, K., Calle, B. orcid.org/0000-0002-9893-9803 et al. (56 more authors) (2023) Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth. Oncogene, 42. pp. 926-937. ISSN 0950-9232

Slovin, S., Hussain, S. orcid.org/0000-0003-1552-511X, Saad, F. et al. (11 more authors) (2019) Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer. Clinical Cancer Research, 25 (15). pp. 4624-4633. ISSN 1078-0432